Join to View Full Profile
601 Elmwood AveRochester, NY 14642
Dr. Burchard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Paul Burchard is a resident physician based in Rochester, NY, with a specialty in surgery. He completed his medical education at West Virginia University School of Medicine in 2018 followed by a residency at the University of Rochester Medical Center. Dr. Burchard has several publications, including studies on topics such as critical care billing, tumor stroma disruption in cholangiocarcinoma, and the impact of carbohydrate antigen on pancreatic cancer survival. His research has been published in reputable journals such as Hospital Pediatrics, Hepatology Communications, Surgery, Annals of Surgical Oncology, and the European Journal of Surgical Oncology, with some articles being cited multiple times.
Education & Training
University of Rochester Medical CenterResidency, Surgery, 2018
West Virginia University School of MedicineClass of 2018
Certifications & Licensure
NY State Medical License 2020 - 2023
Publications & Presentations
PubMed
- 1 citationsImplementing Critical Care Billing on a Pediatric Hospital Medicine Service.Suzanne N Ramazani, Marisa Mauro, Bethany Marbaker, Steven Bondi, Conrad D Gleber
Hospital Pediatrics. 2025-06-01 - Evaluating Opportunities for Critical Care Billing on a Pediatric Hospital Medicine Service.Suzanne N Ramazani, Tina Sosa, Conrad Gleber, Lauren G Solan, Paul R Burchard
Hospital Pediatrics. 2025-01-01 - 4 citationsPan-lysyl oxidase inhibition disrupts fibroinflammatory tumor stroma, rendering cholangiocarcinoma susceptible to chemotherapy.Paul R Burchard, Luis I Ruffolo, Nicholas A Ullman, Benjamin S Dale, Yatee A Dave
Hepatology Communications. 2024-08-01
Press Mentions
- Nam Tai Property Announces the Commencement of Pre-Sale of Nam Tai LongxiAugust 6th, 2021
- Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer ModelAugust 5th, 2021
- Pharmaxis Welcomes Data Presented by University of Rochester Showing PXS-5505 Decreases Tumour Burden in Pre-Clinical Liver Cancer ModelAugust 4th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
